Osteoporosis is a bone disorder characterized by low mineral density and bone mass, affecting 70 % of the U.S. population. Osteoporosis is most common in women than in men. These affected population are at high risk of fragility fracture, which most commonly occurs in wrist, upper arm, knee, hip and spine. Prevalence of osteoporosis is high among people aged 60 years and above. Moreover, estrogen plays a vital role in regulating the bone growth process in women. The rate of bone loss in women increases after menopause, leading to the threat of developing osteoporosis. Annually, 8.9 million fractures are reported to occur from osteoporosis across the globe. Anti-osteoporotic therapy is a treatment intended to increase bone mineral density and control the loss of bone tissue. Anti-osteoporosis can decrease the risk of subsequent fractures by 40%. Most of anti-osteoporosis therapy drugs are derived from the bisphosphonate molecule. Various studies have reported that these drugs can indeed increase bone mineral density (BMD) and reduce the risk of vertebral, hip, and other non-vertebral fractures in women with osteoporosis. The global demand for anti-osteoporosis therapy drugs has increased in the recent years due to increase in the number of people suffering from osteoporosis bone disorder and increase in geriatric population across the globe. Currently, the global anti-osteoporosis therapy and fracture healing market is dominated by the bisphosphonates molecules. Population are at high risk of osteoporosis include women with a family history of osteoporosis and related bone fractures, moderate to heavy alcohol and smoking use, early or surgical menopause, mal-absorption, hyperthyroidism, anorexia nervosa, scoliosis etc.
The global anti-osteoporosis therapy and fracture healing market will continue to dominate osteoporosis therapy market, and is expected to grow at a single digit CAGR during the forecast period (2015-2025)
Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1008
Global Anti-Osteoporosis Therapy and Fracture Healing Market: Drivers and Restraints
Increasing prevalence of osteoporosis in post-menopausal women, increasing incidence of geriatric population, rise in incidence of people suffering from osteoporosis and changing lifestyle impacting bone health are some of the factors driving growth of the global anti-osteoporosis therapy and fracture healing market. In addition, growing investments in R&D for the discovery of innovative drugs and increasing awareness about osteoporosis care are also fueling the growth of the anti-osteoporosis therapy and fracture healing market.
On the other hand, the factors limiting the growth of the global anti-osteoporosis therapy and fracture healing market include, complications and side effects associated with these therapies such as irritable bowel syndrome, nausea, patent expiration of anti-osteoporosis therapies, Influenza-like symptoms and ulcers in stomach and esophagus.
Visit for TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1008
Global Anti-Osteoporosis Therapy and Fracture Healing Market: Segmentation
Global anti-osteoporosis therapy and fracture healing market can be segmented on the basis of route of administration, drug type and geography.
- Route of Administration:
- Drug Type
- Zoledronic acid
- Selective oestrogen receptor modulators (SERM)
- Strontium ranelate
Global Anti-Osteoporosis Therapy and Fracture Healing Market: Overview
Due to rising prevalence of osteoporosis the global anti-osteoporosis and fracture healing market is expected to have a robust growth in the forecast period (2015-2025). Moreover, increasing prevalence of osteoporosis in post-menopausal women and increase in incidence of geriatric population across the globe are likely to fuel the demand for anti-osteoporosis therapy and fracture healing market in upcoming years.
Global Anti-Osteoporosis Therapy and Fracture Healing Market: Region- wise Outlook
North America dominates the global anti-osteoporosis therapy and fracture healing market due to increasing investment in R&D for the discovery of new and innovative drugs, rising incidence of geriatric population, and increasing prevalence of lifestyle associated diseases in the region. Asia-Pacific anti-osteoporosis therapy and fracture healing market is expected to exhibit high growth rates in the forecast period. China and India are expected to be the fastest-growing markets for anti-osteoporosis therapy and fracture healing market in Asia-Pacific. Some of the key factors driving the global anti-osteoporosis therapy and fracture healing market in emerging countries are, growing awareness about osteoporosis care, a large pool of patients, rising incident of geriatric population, changing lifestyles and increasing healthcare expenditure.
Global anti-osteoporosis therapy and fracture healing market is expected to grow over the forecast period contributed to rapid growth of healthcare industry and healthcare expenditure in emerging countries such as India and China, and increasing benefits of anti-osteoporosis therapies over other osteoporosis therapies.
Global Anti-Osteoporosis Therapy and Fracture Healing Market: Key Players
Major players in this market are Actavis plc, Eli Lilly and Company, Merck and Company Inc., Teva Pharmaceutical Industries Ltd., Amgen Inc., F. Hoffmann La Roche Ltd., Novartis International AG., Pfizer, Inc., and GlaxoSmithKline plc.